1. Home
  2. SKE vs ICUI Comparison

SKE vs ICUI Comparison

Compare SKE & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skeena Resources Limited

SKE

Skeena Resources Limited

HOLD

Current Price

$28.02

Market Cap

3.8B

ML Signal

HOLD

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$136.97

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKE
ICUI
Founded
1979
1984
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.5B
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
SKE
ICUI
Price
$28.02
$136.97
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$169.00
AVG Volume (30 Days)
962.2K
266.7K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.62
EPS
N/A
1.20
Revenue
N/A
$2,231,262,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$37,573.35
$4.46
P/E Ratio
N/A
$116.98
Revenue Growth
N/A
N/A
52 Week Low
$13.81
$107.02
52 Week High
$38.77
$160.29

Technical Indicators

Market Signals
Indicator
SKE
ICUI
Relative Strength Index (RSI) 46.48 51.74
Support Level $28.07 $130.66
Resistance Level $34.86 $153.00
Average True Range (ATR) 1.68 4.31
MACD 0.21 -0.35
Stochastic Oscillator 44.71 44.25

Price Performance

Historical Comparison
SKE
ICUI

About SKE Skeena Resources Limited

Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

Share on Social Networks: